Advanced and Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Advanced and Metastatic Colorectal Cancer Market Outlook

Thelansis’s “Advanced and Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced and Metastatic Colorectal Cancer Overview

Approximately 25% of patients are diagnosed with metastatic colorectal cancer, and roughly 50%-60% of those initially diagnosed with colorectal cancer progress to develop metastatic disease. Visceral obesity has been linked to adverse effects on CRC prognosis in men, with about a quarter attributable to genetic predisposition. The liver is the most common site for colorectal cancer metastases, extending to the lungs, bones, brain, or spinal cord. The development period for CRC typically spans several years, underscoring the importance of early diagnosis. Factors such as a previous cancer diagnosis, history of colon polyps, inflammatory bowel diseases, diabetes mellitus, or cholecystectomy can increase the risk of CRC. Surgery is the primary treatment for colon cancer, while chemotherapy is often used as an adjuvant therapy. Approximately 40% of CRC cases with RAS wild type are responsive to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAB) therapy. Metastatic colorectal cancer (mCRC) maintains a dismal prognosis, with an estimated 14% 5-year survival rate. Unlike early-stage CRC, which can be treated effectively with surgery and adjuvant chemotherapy, mCRC remains challenging due to therapy-resistant metastasis-competent cells. Common signs of colorectal cancer include frequent bowel movements, narrow stools, dark stools with blood, fatigue, reduced appetite, unexplained weight loss, and gas pains or stomach cramps.

• The American Cancer Society (ACS) reports an average five-year relative survival rate of 72% for regional metastatic colon cancer and 13% for distant cases. According to the ACS, the five-year survival rate estimate for metastatic rectal cancer is 74% for regional cancer and 17% for distant cancer.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: